Cell-El is pleased to announce that we are opening up recruitment for a new group of children in our study: Children (ages 2-12) diagnosed with ASD who are privately undergoing Stem Cell treatment (SCT) outside of Israel. Cell-El seeks to observe the effects of Stem Cell treatment on the biomarkers we have identified as possibly unique to ASD. We are studying how these Biomarkers change with the application of SCT treatment. Included in the study are behavioral changes possibly observed in these children as well. (see our recent publication regarding our research on these biomarkers – Autism Spectrum Disorder Diagnosis -using a New Panel of Immune- and Inflammatory-related Serum Biomarkers: A Case-Controlled Multicenter Study

Cell-El has chosen to observe the changes in these biomarkers specifically after undergoing SCT as there has been preliminary evidence that stem cells can have an immune-modulating effect on the body. See:
- Therapeutic properties of mesenchymal stem cells for autism spectrum disorders
- Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder .
Parents and clinicians have reported significant changes to the ASD related symptoms after SCT. Cell-El is now investigating if there is an underlying biomedical dysfunction prior to treatment as well as any treatment induced changes both biomedically and as evidenced by improved outward behaviors and symptoms. We hope that Improving our understanding of the value of these biomarkers could lead to utilizing them as a guide to diagnosis and perhaps even treatment choices for ASD.